Latest News - Johnson & Johnson
Top Corporates Hub
Johnson & Johnson
Jim Cramer on Johnson & Johnson: “It’s a Textbook Slowdown Stock”
21.03.2026 16:31
Johnson & Johnson (NYSE:JNJ) is one of the stocks mentioned during the show, as we cover everything Jim Cramer said about the oversold market. Cramer was quite bullish on the company’s stock, as he stated: Yesterday, we got some terrific news from Johnson & Johnson, but because the tape was so ugly, the stock did […]
Monte Rosa J J Supply Deal Refocuses MRT 2359 Prostate Cancer Story
21.03.2026 11:07
Monte Rosa Therapeutics (NasdaqGS:GLUE) announced a new supply agreement with Johnson & Johnson to evaluate MRT-2359 with ERLEADA in metastatic castration resistant prostate cancer. The company is initiating a Phase 2 trial of the MRT-2359 plus ERLEADA combination in this setting. Additional positive clinical data for MRT-2359 in advanced prostate cancer were presented at ASCO GU 2026. Monte Rosa Therapeutics enters this news cycle with its shares at $15.63 and a 1 year return of 169.5%...
Origin Materials and HP Embalagens enter PET cap distribution deal
20.03.2026 11:19
The initial focus is on the 1881 beverage closure format, with further expansion planned.
Johnson & Johnson Prostate Cancer Trial Adds Depth To Valuation Debate
20.03.2026 10:05
Johnson & Johnson (NYSE:JNJ) has entered a clinical supply agreement with GI Innovation to test a bispecific immunotherapy combination in prostate cancer. The collaboration focuses on evaluating J&J’s pasritamig with GI Innovation’s GI-102 in metastatic castration-resistant prostate cancer. The partnership marks an expansion of J&J’s oncology pipeline beyond its recent product launches, including ICOTYDE for psoriasis. For investors following NYSE:JNJ, this move adds a fresh piece to the...
Barclays Sees Continued Strength in Johnson & Johnson (JNJ) Pharma Business
20.03.2026 04:15
Johnson & Johnson (NYSE:JNJ) is included among the 15 Dividend Stocks to Buy for Steady Income. On March 19, Barclays raised its price recommendation on Johnson & Johnson (NYSE:JNJ) to $234 from $217. It kept an Equal Weight rating on the shares. The firm said its analysis confirms the company’s “strong” 23% US pharma growth […]
GI Innovation Announces First Clinical Supply Agreement to Explore Combination Therapy for Prostate Cancer
20.03.2026 01:29
GI Innovation announced on 19th that it has entered into a clinical supply agreement with Johnson & Johnson to evaluate a combination therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) in a phase 1b clinical trial.
Jim Cramer on Johnson & Johnson: “It Should Have Gone Higher, But It Just Shows You How Hard It Is to Buck Stagflation Theories”
19.03.2026 17:15
Johnson & Johnson (NYSE:JNJ) is one of Jim Cramer’s latest stock calls as he shared how to navigate Wednesday’s tough tape. Cramer believes that the stock should have gone higher, as he stated: What can you do on days like today? Well, the investing club… We like to buy, not big, but we’re not sellers. […]
J&J Expands New Drug Portfolio With Icotyde's FDA Approval
19.03.2026 16:11
J&J wins FDA nod for Icotyde, a once-daily oral psoriasis pill, boosting its new drugs portfolio and challenging injectable treatments in a key market.
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
19.03.2026 13:00
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Johnson & Johnson announces U.S. FDA approved Icotyde
19.03.2026 11:55
Johnson & Johnson announced that the U.S. Food and Drug Administration, FDA, has approved Icotyde, an interleukin-23 receptor antagonist for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg who are candidates for systemic therapy or phototherapy. Icotyde is the first and only targeted oral peptide that precisely blocks the IL-23 receptor. “Icotyde delivers something unique in psoriasis treatment – combining s
Global Intracranial Pressure Monitoring Devices Market Size/Share Worth USD 3.71 Billion by 2035 at a 7.4% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, SWOT Analysis)
19.03.2026 08:30
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Intracranial Pressure Monitoring Devices Market size & share revenue was valued at approximately USD 1.89 Billion in 2025 and is expected to reach USD 2.02 Billion in 2026 and is expected to reach around USD 3.71 Billion by 2035, at a CAGR of 7.4% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Medtronic
Johnson & Johnson-Protagonist Therapeutics Partnered New Psoriasis Pill Wins FDA Nod, Shakes Up Competition With AbbVie
19.03.2026 08:25
FDA approves Icotyde, a once-daily psoriasis pill from Johnson & Johnson, sparking new competition in treatment options.
Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis
18.03.2026 12:05
ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety profile in a once-daily pill Approval supported by four phase 3 studies that met all primary endpoints and demonstrated a favorable ...
FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide
18.03.2026 11:49
Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has approved ICOTYDE™ (icotrokinra), an interleukin-23 (IL-23) receptor antagonist for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg who are candidates for systemic therapy or phototherapy.1 ICOTYDE is the first and only targeted oral peptide that precisely blocks the IL-23 receptor.2
Johnson & Johnson Says FDA Approves ICOTYDE, IL-23 Receptor Antagonist For Treatment Of Moderate-To-Severe Plaque Psoriasis
18.03.2026 07:52
Johnson & Johnson introduces the first and only IL-23R targeted oral peptide that delivers complete skin clearance and favorable safety profile in a once-daily pillICOTYDE offers an innovative new option for patients
[Latest] Global Surgical Stapling Devices Market Size/Share Worth USD 10.14 Billion by 2035 at a 7.2% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
18.03.2026 03:30
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Surgical Stapling Devices Market size & share revenue was valued at approximately USD 5.47 Billion in 2025 and is expected to reach USD 5.89 Billion in 2026 and is expected to reach around USD 10.14 Billion by 2035, at a CAGR of 7.2% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Medtronic plc, Ethicon
Johnson & Johnson Drives Innovation in Pulsed Field Ablation with Peru Launch
16.03.2026 15:00
LIMA, Peru, March 16, 2026--Johnson & Johnson announced the arrival in Peru of a new pulsed field ablation (PFA) technology for the treatment of drug-refractory paroxysmal atrial fibrillation. This incorporation represents a significant advance in the approach to cardiac arrhythmias, with benefits in terms of safety, precision, and procedural efficiency.1
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
16.03.2026 11:00
MRT-2359 is an investigational, orally bioavailable, GSPT1-directed molecular glue degrader that has shown compelling clinical activity in combination with androgen receptor (AR) inhibition in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) patients with AR mutations in an ongoing Phase 1/2 clinical study Monte Rosa plans to initiate a new, signal-confirming Phase 2 study of MRT-2359 in combination with apalutamide targeting AR mutant patients in Q3 2026 BOSTON, March
Neurocrine Biosciences: The Song Remains The Same
16.03.2026 09:11
Neurocrine Biosciences has rebounded 60% since April 2025, driven by robust Ingrezza sales and Crenessity's uncontested launch. Read why NBIX stock is a hold.